Prostate cancer proteomics

OMICS A Journal of Integrative Biology

Volumn 15, Issue 3, 2011, Pages 169-171

  Masters, John R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN ISOLATION; PROTEOMICS;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952512777     PISSN: 15362310     EISSN: None     Source Type: Journal    
DOI: 10.1089/omi.2010.0083     Document Type: Article

References (15)

1. Adachi J, Kumar C, Zhang Y, Olsen JV, and Mann M. (2006). The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 7, R80.
2. Andriole GL, Carwford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. (2009). Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360, 1310-1319.
3. Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, et al.; Scandinavian Prostate Cancer Group Study Number 4. (2008). Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 100, 1144-1154.
4. Frankel S, Smith GD, Donovan J, and Neal D. (2003). Screening for prostate cancer. Lancet 361, 1122-1128. (Pubitemid 36369568)
5. Franks LM. (1954). Latent carcinoma. Ann R Coll Surg Engl 15, 236-249.
6. Goo YA, and Goodlett DR. (2010). Advances in proteomic prostate cancer biomarker discovery. J Proteomics 73, 1839-1850.
7. Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, and Bouchal J. (2010). Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis 13, 12-19.
8. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, et al. (2010). Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumors. Eur Urol 58, 12-18.
9. Pilch B, and Mann M. (2006). Large-scale and high-confidence proteomic analysis of human seminal plasma. Genome Biol 7, R40.
10. Schroder FH, Hugosson J, Roobol MJ, Tammeia TL, Ciatto S, Nele V, et al. (2009). Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360, 13230-1328.
11. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914.
12. Sui S, Wang J, Yang B, Song L, Zhang J, Chen M, et al. (2008). Phosphoproteome analysis of the human Chang liver cells using SCX and a complementary mass spectrometric strategy. Proteomics 8, 2024-2034. (Pubitemid 351775782)
13. Tan F, Lu L, Cai Y, Wang J, Xie Y, Wang L, et al. (2008). Proteomic analysis of ubiquitinated proteins in normal hepatocyte cell line Chang liver cells. Proteomics 8, 2885-2896.
14. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. (2004). Prevalence of prostate cancer among men with a prostate-specific antigen level < or=4.0ng per milliliter. N Engl J Med 350, 2239-2246.
15. Xu Z, Zhou X, Lu H, Wu N, Zhao H, Zhang L, et al. (2007). Comparative glycoproteomics based on lectins affinity capture of N-linked glycoproteins from human Chang liver cells and MHCC97-H cells. Proteomics 7, 2358-2370. (Pubitemid 47121528)